Treatment of vasculopathy with prostacyclin and mesenchymal stem cells

A method for preparing a composition comprising a mesenchymal stem cell (MSC) or a culture medium that has been in contact with the MSC and contains one or more components of the MSC for in vivo delivery, comprising contacting the MSC with a prostacyclin.

A pharmaceutical composition comprising treprostinil or a pharmaceutically acceptable salt or ester thereof and a pharmaceutically effective amount of exosomes and a pharmaceutically acceptable carrier, wherein the exosomes are isolated from a mesenchymal stem cell culture comprising mesenchymal stem cells and treprostinil or a pharmaceutically acceptable salt or ester thereof, wherein the treprostinil or pharmaceutically acceptable salt or ester thereof is present in an amount sufficient to increase the amount of vascular endothelial growth factor contained in the mesenchymal stem cell culture and wherein the exosomes have increased VEGF-A gene transcript levels relative to exosomes obtained from a mesenchymal stem cell culture to which a prostacyclin was not added during culturing.